ACSL3 (human, recombinant; aa 45-720)

ACS3|Fatty Acid CoA Ligase 3|LACS 3|Long-chain Acyl-CoA Synthetase 3|Long-chain Fatty Acid-CoA Ligase 3

Long-chain acyl-CoA synthetase 3 (ACSL3) is an enzyme involved in lipid biosesynthesis and fatty acid degradation.{72369} It is composed of short N- and C-terminal domains surrounding an AMP-binding domain.{72370} It is expressed in the brain and prostate and localizes to the endoplasmic reticulum, mitochondria, and lipid droplets.{72369} ACSL3 is activated by a variety of factors, including peroxisome proliferator-activated receptor δ (PPARδ), octamer-binding transcription factor 1 (Oct1), and the liver X receptor (LXR), among others. ACSL3 converts free monounsaturated long-chain fatty acids into fatty acyl-CoA esters, which are used as substrates for phospholipid and glycerolipid biosesynthesis or transported into the mitochondria to be degraded via fatty acid β-oxidation for use as an energy source.{72369,72371,72373} ACSL3-dependent conversion of exogenous MUFAs into fatty acyl-CoA esters can induce resistance to ferroptotic cell death by displacing PUFAs and preventing the accumulation of lipid reactive oxygen species (ROS) in the plasma membrane.{72371,35628} ACSL3 is required for tumor cell survival in non-small cell lung cancer (NSCLC) mouse xenograft models, including those expressing K-Ras containing the glycine-to-aspartate activating mutation at position 12 (K-RasG12D).{72372} It is also highly expressed in tumor tissues isolated from patients with early-stage NSCLC. In contrast, homozygous deletion of ACSL3 is associated with an increased risk of metastasis or recurrence in patients with triple-negative breast cancer (TNBC) receiving adjuvant chemotherapy.{72374} Cayman’s ACSL3 (human, recombinant) protein can be used for ELISA, enzyme activity assay, and Western blot applications.

-80

-80

50 mM Tris pH 8.0, with 150 mM sodium chloride and 10% glycerol

365

≥90% estimated by SDS-PAGE